Clinical trials: Recurrent Cancer
Kidney Cancer
DNA Variations in the Gene in Young Patients With Wilms' Tumor
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that may occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00088803
- Testing
- molecular genetic technique, polymerase chain reaction, polymorphism analysis
- Where
- 232 sites in United States, Australia and 5 more
- Volunteers
- 471 people, healthy volunteers welcome
- Sponsor
- Children's Oncology Group
Glioblastoma, Astrocytoma
Stem Cell Transplant for High Risk Central Nervous System (CNS) Tumors
The primary goal of this study is to determine if a stem cell transplant in patients with newly diagnosed high risk CNS tumors (glioblastoma multiforme [GBM], high grade astrocytoma, pineoblastoma, rhabdoid tumor, supratentorial…
- Conditions
- Glioblastoma, Astrocytoma, Pineoblastoma, Rhabdoid Tumor
- Trial name
- NCT00179803
- Testing
- Stem Cell Transplant
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Ann & Robert H Lurie Children's Hospital of Chicago
Chronic Myeloproliferative Disorders, Leukemia
Combination Chemotherapy, Bone Marrow Transplant, and Post Transplant Cyclophosphamide for Hematologic Cancer
RATIONALE: Giving chemotherapy before a donor bone marrow transplant helps stop the growth of cancer and abnormal cells and helps stop the patient's immune system from rejecting the donor's stem cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00134017
- Testing
- Busulfan, Cyclophosphamide
- Where
- United States
- Volunteers
- 142 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Head Cancer Neck
IReC-Bio and IReC Registry
IReC is the world's first centre for recurrent head and neck cancers. We have the ambitious aim to create a centre of international excellence and set international standards in the curative treatment of recurrent head and neck…
- Trial name
- IReC-Bio (NCT05885490)
- Volunteers
- 10,000,000 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma
ABI-007 in Treating Patients With Persistent or Recurrent Cervical Cancer
This phase II trial is studying how well ABI-007 works in treating patients with persistent or recurrent cervical cancer. Drugs used in chemotherapy, such as ABI-007, work in different ways to stop the growth of tumor cells…
- Conditions
- Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Small Cell Carcinoma, Cervical Squamous Cell Carcinoma
- Trial name
- NCT00309959
- Testing
- Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Laboratory Biomarker Analysis
- Where
- 26 sites in United States
- Volunteers
- 37 people
- Sponsor
- Gynecologic Oncology Group
Medulloblastoma, Neuroectodermal Tumor
Vaccine Immunotherapy for Recurrent Medulloblastoma and Primitive Neuroectodermal Tumor
Immunotherapy is a specific approach to treating cancer that has shown promise in adult patients for the treatment of melanoma, malignant brain tumors, and other cancers.
- Trial name
- Re-MATCH (NCT01326104)
- Testing
- TTRNA-xALT, TTRNA-DCs
- Where
- 3 sites in United States
- Volunteers
- 26 people
- Sponsor
- University of Florida
Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma
506U78 in Treating Patients With Lymphoma
Phase II trial to study the effectiveness of 506U78 in treating patients who have lymphoma that has not been treated previously or that has not responded to previous treatment.
- Conditions
- Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma
- Trial name
- NCT00005080
- Testing
- nelarabine
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- National Cancer Institute (NCI)
Nasopharyngeal Neoplasms
Peptide Vaccine to Prevent Recurrence of Nasopharyngeal Cancer
This study will examine the effectiveness and side effects of an experimental vaccine to prevent recurrence of nasopharyngeal cancer.
- Trial name
- NCT00078494
- Testing
- EBV-LMP-2
- Where
- United States
- Volunteers
- 99 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Advanced Malignant Solid Neoplasm, Recurrent Ependymal Tumor
Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
This phase II Pediatric MATCH trial studies how well ulixertinib works in treating patients with solid tumors that have spread to other places in the body (advanced), non-Hodgkin lymphoma, or histiocytic disorders that have a…
- Conditions
- Advanced Malignant Solid Neoplasm, Recurrent Ependymal Tumor, Recurrent Ewing Sarcoma, Recurrent Glioma
- Trial name
- NCT03698994
- Testing
- Pharmacokinetic Study, Ulixertinib
- Where
- 107 sites in United States, Puerto Rico
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Cancer, Quality of Life
Cetuximab + Best Supportive Care Compared With Best Supportive Care Alone in Metastatic Epidermal Growth Factor Receptor-Positive Colorectal Cancer
RATIONALE: Monoclonal antibodies, such as cetuximab, can target tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00079066
- Testing
- cetuximab, quality-of-life assessment
- Where
- 33 sites in Australia, Canada
- Volunteers
- 572 people
- Sponsor
- NCIC Clinical Trials Group
Metastatic Melanoma
Open-Label Study of TPI 287 for Patients With Metastatic Melanoma
The goal of this clinical research study is to find the highest tolerable dose of TPI 287 that can be given to patients with metastatic melanoma. Researchers want to find out if TPI 287 can control the disease.
- Trial name
- NCT01340729
- Testing
- TPI 287
- Where
- United States
- Sponsor
- M.D. Anderson Cancer Center
Brain and Central Nervous System Tumors
Cisplatin and Temozolomide in Treating Young Patients With Malignant Glioma
RATIONALE: Drugs used in chemotherapy, such as cisplatin and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00360945
- Testing
- cisplatin, temozolomide, fluorescence in situ hybridization
- Where
- 23 sites in France, Ireland and 1 more
- Volunteers
- 87 people
- Sponsor
- Children's Cancer and Leukaemia Group
Brain and Central Nervous System Tumors, Melanoma (Skin)
Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Melanoma or Brain Tumors
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Conditions
- Brain and Central Nervous System Tumors, Melanoma (Skin), Metastatic Cancer
- Trial name
- NCT00002754
- Testing
- monoclonal antibody Me1-14 F(ab')2
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Duke University
Cervical Cancer
Gemcitabine and Cisplatin in Treating Patients With Refractory or Recurrent Cancer of the Cervix
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00006482
- Testing
- cisplatin, gemcitabine hydrochloride
- Where
- 34 sites in United States, Canada
- Sponsor
- Gynecologic Oncology Group
Colorectal Cancer
A Multicenter Study on the Safety and Functionality Evaluation of Anastomotic Redo Surgery
To analyze the influencing factors of the success of redo surgery due to anastomotic fistula or anastomotic recurrence after rectal cancer surgery and to evaluate the anal function of patients
- Trial name
- NCT07279961
- Volunteers
- 143 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Brain and Central Nervous System Tumors, Intraocular Melanoma
Monoclonal Antibody Therapy in Treating Patients With Leptomeningeal Cancer
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Conditions
- Brain and Central Nervous System Tumors, Intraocular Melanoma, Lung Cancer, Melanoma (Skin)
- Trial name
- NCT00003022
- Testing
- iodine I 131 monoclonal antibody 3F8
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
NSCLC
Photon Versus Particle Therapy for Recurrent Lung Cancer; a Planning Study Based on a Reference Dataset of Patients.
Patients with lung cancer may develop a second primary tumor or recurrent disease after previous radiotherapy. Surgical salvage therapy is the mainstay of therapeutic options.
- Trial name
- NCT02029222
- Where
- Netherlands
- Volunteers
- 25 people
- Sponsor
- Maastricht Radiation Oncology
Recurrent Solid Tumor, Refractory Solid Tumor
ODSH + ICE Chemotherapy in Pediatric Solid Tumors
This study will be with pediatric patients who have refractory/recurrent solid tumors. They will receive standard chemotherapy (ICE) and we are investigating if the addition of a new drug, ODSH, will help to increase the time of…
- Conditions
- Recurrent Solid Tumor, Refractory Solid Tumor, Sarcoma, Wilms' Tumor
- Trial name
- NCT02164097
- Testing
- ODSH
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- New York Medical College
Colorectal Tumors
Effect of Peritoneal Lavage With Clindamycin-Gentamicin Solution & Oncologic Outcome
Antibiotic lavage reduces bacterial contamination and decreases SSI infection rate. SSI leads to an immunocompromised situation, leaving unattended the neoplasm.
- Trial name
- NCT02399059
- Testing
- Antibiotic lavage, Normal saline lavage
- Volunteers
- 106 people
- Sponsor
- Hospital General Universitario Elche
Graft Versus Host Disease, Leukemia
Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Other Hematologic or Metabolic Diseases
RATIONALE: Umbilical cord blood transplantation may be able to replace cells destroyed by chemotherapy or radiation therapy. PURPOSE: Phase II trial to study the effectiveness of umbilical cord blood transplantation in treating…
- Conditions
- Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes, Thymic Carcinoma
- Trial name
- NCT00003662
- Testing
- anti-thymocyte globulin, busulfan, cyclophosphamide
- Where
- 15 sites in United States
- Volunteers
- 90 people
- Sponsor
- Roswell Park Cancer Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.